Best name badge at #MHVF – who can help? pic.twitter.com/dsw4n2OAza
— coppedge (@coppedge) March 10, 2015
This isn’t the first time a startup’s broadcasted its funding needs at a conference – but a lack of originality doesn’t meant it won’t draw eyes. Wisconsin oncology startup Peptimed definitely got some attention at this week’s Mid-America Healthcare Venture Forum in Chicago. The angel-funded startup needs $8 million to take it through Phase 2 trials – and, if all goes to plan, the market.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The RNA cancer therapeutics company uses small interfering RNA, or siRNA, to target receptors on late-stage cancer cells – inhibiting the expression of a protein called EVI1 to in turn block cell division and activate apoptosis. When the company mixes its RNA drug with a polypeptide, it self-assembles into a nanoparticle, chief business officer – and wearer of the name tag – Thomas Primiano said. It’s targeting late-stage breast, ovarian, pancreatic and lung cancers. It’s meant to help patients who have cancers that have outwitted all other treatment options.
The startup’s funded with about $1 million from Watson Bioventures, a Chicago-area angel group. It needs to scale up GMP manufacturing before it gets to clinical trials, Primiano said – a process that’ll cost about $1.5 million.
Keeping startups in business is a nebulous business, so you could call Peptimed a comeback kid. Primiano actually founded a separate company, called Nano Oncology, in 2010 – but the state and federal grant-funded operation declared bankruptcy in 2012. Rather than shut down entirely, Primiano allowed the angel group to relaunch the company under a new name, and came on as chief business officer. And now it’s looking for funding, and accelerated approval.